{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:11:29Z","timestamp":1792714289228,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ebiom.2024.105385","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T12:01:43Z","timestamp":1728648103000},"page":"105385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID"],"prefix":"10.1016","volume":"109","author":[{"given":"Puran","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotta","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"S\u00f6derdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.I.Edvard","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vesterbacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wullimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Cuapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Akber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Bogdanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Muschiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"\u00c5berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret S\u00e4llberg","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Buggert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0908-7387","authenticated-orcid":false,"given":"Hans-Gustaf","family":"Ljunggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2024.105385_bib1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A\u00a0novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2024.105385_bib2","doi-asserted-by":"crossref","first-page":"m1036","DOI":"10.1136\/bmj.m1036","article-title":"Covid-19: WHO declares pandemic because of \u201calarming levels\u201d of spread, severity, and inaction","volume":"368","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ebiom.2024.105385_bib3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","article-title":"The biological and clinical significance of emerging SARS-CoV-2 variants","volume":"22","author":"Tao","year":"2021","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.ebiom.2024.105385_bib4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041390","article-title":"The evolution and biology of SARS-CoV-2 variants","volume":"12","author":"Telenti","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.ebiom.2024.105385_bib5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/cid\/ciaa863","article-title":"COVID-19 in immunocompromised hosts: what we know so far","volume":"72","author":"Fung","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2024.105385_bib6","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.csbj.2021.04.061","article-title":"An overview of current COVID-19 vaccine platforms","volume":"19","author":"Nagy","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.ebiom.2024.105385_bib7","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","article-title":"mRNA-based therapeutics: looking beyond COVID-19 vaccines","volume":"403","author":"Parhiz","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2024.105385_bib8","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2024.105385_bib9","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2024.105385_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2024.105385_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ebiom.2024.105385_bib12","article-title":"Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review","volume":"8","author":"Kreuzberger","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ebiom.2024.105385_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12985-022-01858-3","article-title":"Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis","volume":"19","author":"Mehrabi Nejad","year":"2022","journal-title":"Virol J"},{"key":"10.1016\/j.ebiom.2024.105385_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101965","article-title":"Vaccines and therapeutics for immunocompromised patients with COVID-19","volume":"59","author":"Shoham","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ebiom.2024.105385_bib15","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/infdis\/jiad174","article-title":"COVID-19 vaccination in patients with cancer and patients receiving HSCT or CAR-T therapy: immune response, real-world effectiveness, and implications for the future","volume":"228","author":"Hall","year":"2023","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.ebiom.2024.105385_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104700","article-title":"Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID","volume":"94","author":"Chen","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ebiom.2024.105385_bib18","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s10875-022-01283-9","article-title":"Neutralizing SARS-CoV-2 antibodies in commercial immunoglobulin products give patients with X-linked agammaglobulinemia limited passive immunity to the omicron variant","volume":"42","author":"Lindahl","year":"2022","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.ebiom.2024.105385_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40259-021-00511-9","article-title":"SARS-CoV-2 neutralization in convalescent plasma and commercial lots of plasma-derived immunoglobulin","volume":"36","author":"Volk","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.ebiom.2024.105385_bib20","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10875-023-01486-8","article-title":"SARS-CoV-2 antibodies in commercial immunoglobulin products show markedly reduced cross-reactivities against omicron variants","volume":"43","author":"Lindahl","year":"2023","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.ebiom.2024.105385_bib21","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.immuni.2022.07.005","article-title":"Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination","volume":"55","author":"Gao","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ebiom.2024.105385_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg9452","article-title":"Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states","volume":"15","author":"M\u00fcller","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2024.105385_bib23","doi-asserted-by":"crossref","first-page":"eadh0687","DOI":"10.1126\/sciimmunol.adh0687","article-title":"SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19","volume":"8","author":"Cai","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ebiom.2024.105385_bib24","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2024.105385_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104661","article-title":"Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people\u00a0with\u00a0HIV - a prospective observational cohort study","volume":"93","author":"Heftdal","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ebiom.2024.105385_bib26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","article-title":"Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum","volume":"399","author":"Dejnirattisai","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2024.105385_bib27","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2024.105385_bib28","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1473-3099(23)00122-6","article-title":"Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study","volume":"23","author":"Arbel","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2024.105385_bib29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S2213-2600(23)00306-5","article-title":"Effectiveness of BNT162b2 BA.4\/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study","volume":"11","author":"Tartof","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ebiom.2024.105385_bib30","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41591-022-01700-x","article-title":"Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant","volume":"28","author":"Gao","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2024.105385_bib31","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424004213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424004213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:38:23Z","timestamp":1732063103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396424004213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"alternative-id":["S2352396424004213"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105385","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105385"}}